2025
SJR Q2
JCR Q2 · 2,5
54 eşleşen makale
SCIE
Dergi ayrıntısı
Journal of Cardiovascular Pharmacology
- Yayıncı
- Lippincott Williams and Wilkins
- Ülke
- United States · Northern America
- Tür
- journal
- ISSN
-
0160244615334023
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,676
- Quartile Q2
- H-Index 113
- Atıf/yayın 2,09
- Doküman (3y) 471
- Atıf (3y) 977
Clarivate
Web of Science · JCR · 2025
- JCR Q Q2
- JIF 2,5
- 5Y JIF 2,4
- JCI 0,55
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cardiology and Cardiovascular Medicine Q2
- Medicine (miscellaneous) Q2
- Pharmacology Q2
Alanlar
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Cardiac & Cardiovascular System | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q2 | 0,676 | 2,5 | 2,4 | 0,55 | Q3 | 113 |
| 2024 | Q2 | Q2 | 0,684 | 2,2 | 2,5 | 0,56 | Q3 | 111 |
| 2023 | Q2 | Q2 | 0,61 | 2,6 | 2,5 | 0,68 | Q2 | 111 |
| 2022 | Q2 | Q3 | 0,641 | 3 | 3 | 0,71 | Q2 | 111 |
| 2021 | Q2 | Q3 | 0,694 | 3,3 | 3,1 | 0,73 | Q2 | 111 |
| 2020 | Q2 | Q2 | 0,762 | 3,1 | 2,8 | 0,74 | Q2 | 111 |
| 2019 | Q2 | Q2 | 0,8 | 2,6 | 2,3 | 0,75 | Q2 | 111 |
| 2018 | — | Q3 | — | 2,4 | 2,3 | 0,7 | Q2 | — |
| 2017 | Q2 | Q3 | 0,917 | 2,2 | 2,2 | 0,7 | Q2 | 111 |
| 2016 | Q2 | Q3 | 0,939 | 2,2 | 2,2 | — | — | 111 |
| 2015 | Q2 | Q2 | 0,987 | 2,5 | 2,3 | — | — | 111 |
| 2014 | Q1 | Q2 | 0,992 | 2,1 | 2,2 | — | — | 111 |
| 2013 | Q2 | Q3 | 1,019 | 2,1 | 2,3 | — | — | 111 |
| 2012 | Q1 | Q2 | 1,068 | 2,4 | 2,6 | — | — | 111 |
| 2011 | Q1 | Q2 | 0,939 | 2,3 | 2,3 | — | — | 111 |
| 2010 | Q1 | Q2 | 1,173 | 2,4 | 2,4 | — | — | 111 |
| 2009 | — | Q2 | — | 2,8 | 2,1 | — | — | — |
| 2008 | — | Q2 | — | 2,3 | 1,8 | — | — | — |
| 2007 | — | Q2 | — | 2 | 1,8 | — | — | — |
| 2006 | — | Q3 | — | 1,6 | — | — | — | — |
| 2005 | — | Q3 | — | 1,3 | — | — | — | — |
| 2004 | — | Q2 | — | 1,6 | — | — | — | — |
| 2003 | — | Q2 | — | 1,9 | — | — | — | — |
| 2002 | — | Q2 | — | 1,6 | — | — | — | — |
| 2001 | — | Q2 | — | 1,6 | — | — | — | — |
| 2000 | — | Q1 | — | 2,4 | — | — | — | — |
| 1999 | — | Q2 | — | 2 | — | — | — | — |
| 1998 | — | Q2 | — | 1,7 | — | — | — | — |
| 1997 | — | Q2 | — | 1,5 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q3 | 111/237 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 205/356 |
| 2024 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q3 | 111/231 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 209/352 |
| 2023 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 84/222 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 173/354 |
| 2022 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q2 | 72/143 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 157/278 |
| 2021 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q2 | 75/143 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 162/279 |
| 2020 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 71/142 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 160/276 |
| 2019 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 62/138 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 147/271 |
| 2018 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q2 | 69/136 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 151/267 |
| 2017 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q2 | 66/128 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 155/261 |
| 2016 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 65/126 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 142/257 |
| 2015 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 55/124 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 116/255 |
| 2014 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 60/123 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 139/255 |
| 2013 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 65/125 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 142/256 |
| 2012 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 57/124 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 115/261 |
| 2011 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 55/117 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 123/261 |
| 2010 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 47/114 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 119/252 |
| 2009 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 31/95 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 84/237 |
| 2008 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 35/79 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 110/219 |
| 2007 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 33/75 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 110/205 |
| 2006 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 38/74 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 117/199 |
| 2005 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | — | 43/72 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 131/193 |
| 2004 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 34/71 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 106/187 |
| 2003 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 27/70 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 80/185 |
| 2002 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 24/66 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 88/188 |
| 2001 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 25/65 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 79/186 |
| 2000 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | — | 15/63 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | — | 39/181 |
| 1999 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 17/67 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 46/175 |
| 1998 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 18/62 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 51/178 |
| 1997 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | — | 19/62 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 57/157 |